|
Phase II study of erlotinib in advanced non-small cell lung cancer patients with leptomeningeal metastasis. |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma; Kyowa Hakko Kirin; Ono Pharmaceutical; Taiho Pharmaceutical |
Research Funding - Novartis (Inst) |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Research Funding - AstraZeneca; Chugai Pharma; Shimadzu |
|
|
No Relationships to Disclose |
|
|
Honoraria - AstraZeneca; Chugai Pharma; Kyowa Hakko Kirin; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical |
Research Funding - Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst); Nippon Boehringer Ingelheim (Inst); Novartis (Inst); Ono Pharmaceutical (Inst) |
|
|
No Relationships to Disclose |